第七部分
1 中国医学会妇产科分会绝经学组.中国绝经管理与绝经激素治疗指南（2018）[J].协和医学杂志，2018,9(6)512-525.
2 陈蓉，罗敏.早发性卵巢功能不全的相关术语[J].中国实用妇科与产科杂志，2023.39(9): 869-891
3 孙蓬然，冷金花，郎景和.绝经后内异症——北京协和医院20年69例患者的回顾分析[C]. 2013.
4 A Melin, C Lundholm, N Malki, et al. Hormonal and surgical treatments for endometriosis and risk of epithelial ovarian cancer[J].Acta Obstet Gynecol Scand.2013 May;92(5):546-54.
5 Brinton LA, Gridley G, Persson I, et al. Cancer risk after a hospital discharge diagnosis of endometriosis[J].Am J Obstet Gynecol.1997;176:572-579.
6 European Menopause and Andropause Society. EMAS position statement: Managing the menopause in women with a past history of endometriosis[J]. Maturitas.2010 Sep;67(1):94-7.
7 F Taniguchi, T Harada, H Kobayashi, et al. Clinical characteristics of patients in Japan with ovarian cancer presumably arising from ovarian endometrioma [J]. Gynecol Obstet Invest.2014;77(2):104-10.
8 Gemmell LC, et al. The management of menopause in women with a history of endometriosis: a systematic review[J].Hum Reprod Update.2017 Jul 1; 23(4): 481-500.
9 Guideline for Gynecological Practice in Japan 2020 by the JSOG (Japan Society of Obstetrics and Gynecology).
10 H Kobayashi, K Sumimoto, N Moniwa, et al. Risk of developing ovarian cancer among women with ovarian endometrioma: a cohort study in Shizuoka, Japan[J].Int J Gynecol Cancer.2007 Jan-Feb;17(1):37-43.
11 Hermens M, van Altena AM, Nieboer TE, et al. Incidence of endometrioid and clear cell ovarian cancer in histological proven endometriosis: the ENOCA population-based cohort study[J].Am J Obstet Gynecol.2020;223:107.e101-107.e111.
12 Kobayashi H, Yamada Y, Kawahara N, et al. Integrating modern approaches to pathogenetic concepts of malignant transformation of endometriosis[J].Oncol Rep.2019 Mar;41(3):1729-1738.
13 Krina t Zondervan,et al.Endometriosis[J].N EngI J Med.2020;382(13):1244-1256.
14 M Nishida, K Watanabe, N Sato, et al. Malignant transformation of ovarian endometriosis[J].Gynecol Obstet Invest.2000;50(Suppl 1):18-25.
15 Melin A, Spare'n P, Bergqvist A. The risk of cancer and the role of parity among women with endometriosis[J].Hum Reprod.2007; 22: 3021-3026.
16 Nezhat FR, Apostol R, Nezhat C, Pejovic T. New insights in the pathophysiology of ovarian cancer and implications for screening and prevention[J]. Am J Obstet Gynecol.2015 Sep;213(3):262-7.
17 Oral E, Sozen I, Uludag S, et al. The prevalence of endometrioma and associated malignant transformation in women over 40 years of age[J]. J Gynecol Obstet Hum Reprod.2020 May; 49(5):101725.
18 Punnonen R, Klemi PJ, Nikkanen V. Postmenopausal endometriosis[J].Eur J Obstet Gynecol Reprod Biol. 1980 Dec; 11(3): 195-200.
19 Rozenberg S, et. al. Should we abstain from treating women with endometriosis using menopausal hormone therapy, for fear of an increased ovarian cancer risk?[J].Climacteric.2015;18(4):448-52.
20 Sampson JA. Benign and malignant endometrial implants in the peritoneal cavity and their relation to certain ovarian tumors[J].Surg Gynecol Obstet. 1924; 38: 287-311.
21 Taniguchi F. New knowledge and insights about the malignant transformation of endometriosis[J]. J Obstet Gynaecol Res.2017 Jul;43(7):1093-1100.
22 Thombre Kulkarni M, Shafrir A, Farland LV, et al. Association between laparoscopically confirmed endometriosis and risk of early natural menopause[J]. JAMA Netw Open.2022 5:e2144391.
23 Wentzensen N, Poole EM, Trabert B, et al. Ovarian Cancer Risk Factors by Histologic Subtype:An Analysis From the Ovarian Cancer Cohort Consortium[J].J Clin Oncol.2016 Aug 20;34(24):2888-98.
24 Wyatt J, Fernando SM, Powell SG, et al. The role of iron in the pathogenesis of endometriosis: a systematic review[J].Hum Reprod Open.2023 Jul 27; 2023(3): hoad033.
25 Xu B, Hamada S, and Kitawaki J et al. Possible involvement of loss of heterozygosity in malignant transformation of ovarian endometriosis[J].Gynecol Oncol.2011 Feb;120:239-246.
26 Yoldemir T. Evaluation and management of endometriosis[J].Climacteric.2023 Jun;26(3):248-255.
27 Zanello M, et. al. Hormonal Replacement Therapy in Menopausal Women with History of Endometriosis:A Review of Literature[J].Medicina(Kaunas).2019 Aug 14; 55(8): 477.
28 日本産科婦人科学会，婦人科腫瘍委員会子宮内膜症の癌化の頻度と予防に関する小委員会.本邦における子宮内膜症の癌化の頻度と予防に関する疫学研究.
29 徐冰，楠木泉，濱田新七，趙鵬，馬小平，北脇城.子宮内膜症性嚢胞由来卵巣癌における Loss of Heterozygosity (LOH)の意義.第31回日本エンドメトリオーシス学会.（日本京都，2010年1月16日大会专题发言）
30 徐冰，楠木泉，濱田新七，北脇城.子宮内膜症性嚢胞由来卵巣癌におけるLOH の意義.日本エンドメトオーシス研究会会誌.2010,31: 75.
31 徐冰，北脇城，石原広章，濱田新七，楠木泉，本庄英雄。子宮内膜症性嚢胞由来卵巣癌における癌関連遺伝子の変異、loss of heterozygosity (LOH)、およびタンパク発現の変化.日本エンドメトオーシス研究会会誌. 2008, vol.29, 94-96.